Skip to content

Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

Research output: Contribution to journalArticle

Standard

Status of care for end stage kidney disease in countries and regions worldwide : international cross sectional survey. / Bello, Aminu K; Levin, Adeera; Lunney, Meaghan; Osman, Mohamed A; Ye, Feng; Ashuntantang, Gloria E; Bellorin-Font, Ezequiel; Benghanem Gharbi, Mohammed; Davison, Sara N; Ghnaimat, Mohammad; Harden, Paul; Htay, Htay; Jha, Vivekanand; Kalantar-Zadeh, Kamyar; Kerr, Peter G; Klarenbach, Scott; Kovesdy, Csaba P; Luyckx, Valerie A; Neuen, Brendon L; O'Donoghue, Donal; Ossareh, Shahrzad; Perl, Jeffrey; Rashid, Harun Ur; Rondeau, Eric; See, Emily; Saad, Syed; Sola, Laura; Tchokhonelidze, Irma; Tesar, Vladimir; Tungsanga, Kriang; Turan Kazancioglu, Rumeyza; Wang, Angela Yee-Moon; Wiebe, Natasha; Yang, Chih-Wei; Zemchenkov, Alexander; Zhao, Ming-Hui; Jager, Kitty J; Caskey, Fergus; Perkovic, Vlado; Jindal, Kailash K; Okpechi, Ikechi G; Tonelli, Marcello; Feehally, John; Harris, David C; Johnson, David W.

In: BMJ, Vol. 367, l5873 , 31.10.2019.

Research output: Contribution to journalArticle

Harvard

Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, GE, Bellorin-Font, E, Benghanem Gharbi, M, Davison, SN, Ghnaimat, M, Harden, P, Htay, H, Jha, V, Kalantar-Zadeh, K, Kerr, PG, Klarenbach, S, Kovesdy, CP, Luyckx, VA, Neuen, BL, O'Donoghue, D, Ossareh, S, Perl, J, Rashid, HU, Rondeau, E, See, E, Saad, S, Sola, L, Tchokhonelidze, I, Tesar, V, Tungsanga, K, Turan Kazancioglu, R, Wang, AY-M, Wiebe, N, Yang, C-W, Zemchenkov, A, Zhao, M-H, Jager, KJ, Caskey, F, Perkovic, V, Jindal, KK, Okpechi, IG, Tonelli, M, Feehally, J, Harris, DC & Johnson, DW 2019, 'Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey', BMJ, vol. 367, l5873 . https://doi.org/10.1136/bmj.l5873

APA

Bello, A. K., Levin, A., Lunney, M., Osman, M. A., Ye, F., Ashuntantang, G. E., ... Johnson, D. W. (2019). Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ, 367, [l5873 ]. https://doi.org/10.1136/bmj.l5873

Vancouver

Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019 Oct 31;367. l5873 . https://doi.org/10.1136/bmj.l5873

Author

Bello, Aminu K ; Levin, Adeera ; Lunney, Meaghan ; Osman, Mohamed A ; Ye, Feng ; Ashuntantang, Gloria E ; Bellorin-Font, Ezequiel ; Benghanem Gharbi, Mohammed ; Davison, Sara N ; Ghnaimat, Mohammad ; Harden, Paul ; Htay, Htay ; Jha, Vivekanand ; Kalantar-Zadeh, Kamyar ; Kerr, Peter G ; Klarenbach, Scott ; Kovesdy, Csaba P ; Luyckx, Valerie A ; Neuen, Brendon L ; O'Donoghue, Donal ; Ossareh, Shahrzad ; Perl, Jeffrey ; Rashid, Harun Ur ; Rondeau, Eric ; See, Emily ; Saad, Syed ; Sola, Laura ; Tchokhonelidze, Irma ; Tesar, Vladimir ; Tungsanga, Kriang ; Turan Kazancioglu, Rumeyza ; Wang, Angela Yee-Moon ; Wiebe, Natasha ; Yang, Chih-Wei ; Zemchenkov, Alexander ; Zhao, Ming-Hui ; Jager, Kitty J ; Caskey, Fergus ; Perkovic, Vlado ; Jindal, Kailash K ; Okpechi, Ikechi G ; Tonelli, Marcello ; Feehally, John ; Harris, David C ; Johnson, David W. / Status of care for end stage kidney disease in countries and regions worldwide : international cross sectional survey. In: BMJ. 2019 ; Vol. 367.

Bibtex

@article{cb4c99307e0b4f538a23c7156385d088,
title = "Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey",
abstract = "OBJECTIVE: To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management.DESIGN: International cross sectional survey.SETTING: International Society of Nephrology (ISN) survey of 182 countries from July to September 2018.PARTICIPANTS: Key stakeholders identified by ISN's national and regional leaders.MAIN OUTCOME MEASURES: Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management.RESULTS: Responses were received from 160 (87.9{\%}) of 182 countries, comprising 97.8{\%} (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42{\%}) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10{\%}) of 53 African countries reported these data. Of 159 countries, 102 (64{\%}) provided public funding for kidney replacement therapy. Sixty eight (43{\%}) of 159 countries charged no fees at the point of care delivery and 34 (21{\%}) made some charge. Haemodialysis was reported as available in 156 (100{\%}) of 156 countries, peritoneal dialysis in 119 (76{\%}) of 156 countries, and kidney transplantation in 114 (74{\%}) of 155 countries. Dialysis and kidney transplantation were available to more than 50{\%} of patients in only 108 (70{\%}) and 45 (29{\%}) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81{\%}) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level.CONCLUSIONS: These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.",
author = "Bello, {Aminu K} and Adeera Levin and Meaghan Lunney and Osman, {Mohamed A} and Feng Ye and Ashuntantang, {Gloria E} and Ezequiel Bellorin-Font and {Benghanem Gharbi}, Mohammed and Davison, {Sara N} and Mohammad Ghnaimat and Paul Harden and Htay Htay and Vivekanand Jha and Kamyar Kalantar-Zadeh and Kerr, {Peter G} and Scott Klarenbach and Kovesdy, {Csaba P} and Luyckx, {Valerie A} and Neuen, {Brendon L} and Donal O'Donoghue and Shahrzad Ossareh and Jeffrey Perl and Rashid, {Harun Ur} and Eric Rondeau and Emily See and Syed Saad and Laura Sola and Irma Tchokhonelidze and Vladimir Tesar and Kriang Tungsanga and {Turan Kazancioglu}, Rumeyza and Wang, {Angela Yee-Moon} and Natasha Wiebe and Chih-Wei Yang and Alexander Zemchenkov and Ming-Hui Zhao and Jager, {Kitty J} and Fergus Caskey and Vlado Perkovic and Jindal, {Kailash K} and Okpechi, {Ikechi G} and Marcello Tonelli and John Feehally and Harris, {David C} and Johnson, {David W}",
year = "2019",
month = "10",
day = "31",
doi = "10.1136/bmj.l5873",
language = "English",
volume = "367",
journal = "BMJ",
issn = "0959-8138",
publisher = "BMJ Publishing Group",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Status of care for end stage kidney disease in countries and regions worldwide

T2 - international cross sectional survey

AU - Bello, Aminu K

AU - Levin, Adeera

AU - Lunney, Meaghan

AU - Osman, Mohamed A

AU - Ye, Feng

AU - Ashuntantang, Gloria E

AU - Bellorin-Font, Ezequiel

AU - Benghanem Gharbi, Mohammed

AU - Davison, Sara N

AU - Ghnaimat, Mohammad

AU - Harden, Paul

AU - Htay, Htay

AU - Jha, Vivekanand

AU - Kalantar-Zadeh, Kamyar

AU - Kerr, Peter G

AU - Klarenbach, Scott

AU - Kovesdy, Csaba P

AU - Luyckx, Valerie A

AU - Neuen, Brendon L

AU - O'Donoghue, Donal

AU - Ossareh, Shahrzad

AU - Perl, Jeffrey

AU - Rashid, Harun Ur

AU - Rondeau, Eric

AU - See, Emily

AU - Saad, Syed

AU - Sola, Laura

AU - Tchokhonelidze, Irma

AU - Tesar, Vladimir

AU - Tungsanga, Kriang

AU - Turan Kazancioglu, Rumeyza

AU - Wang, Angela Yee-Moon

AU - Wiebe, Natasha

AU - Yang, Chih-Wei

AU - Zemchenkov, Alexander

AU - Zhao, Ming-Hui

AU - Jager, Kitty J

AU - Caskey, Fergus

AU - Perkovic, Vlado

AU - Jindal, Kailash K

AU - Okpechi, Ikechi G

AU - Tonelli, Marcello

AU - Feehally, John

AU - Harris, David C

AU - Johnson, David W

PY - 2019/10/31

Y1 - 2019/10/31

N2 - OBJECTIVE: To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management.DESIGN: International cross sectional survey.SETTING: International Society of Nephrology (ISN) survey of 182 countries from July to September 2018.PARTICIPANTS: Key stakeholders identified by ISN's national and regional leaders.MAIN OUTCOME MEASURES: Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management.RESULTS: Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level.CONCLUSIONS: These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.

AB - OBJECTIVE: To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management.DESIGN: International cross sectional survey.SETTING: International Society of Nephrology (ISN) survey of 182 countries from July to September 2018.PARTICIPANTS: Key stakeholders identified by ISN's national and regional leaders.MAIN OUTCOME MEASURES: Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management.RESULTS: Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level.CONCLUSIONS: These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.

U2 - 10.1136/bmj.l5873

DO - 10.1136/bmj.l5873

M3 - Article

VL - 367

JO - BMJ

JF - BMJ

SN - 0959-8138

M1 - l5873

ER -